Top developments and predictions for the Life Sciences & Healthcare Sector in China

China

We take a look back at the top 10 developments of 2019 and towards what lies ahead with our top 10 predictions of 2020, for you and your business operating in China.

Last year saw a lot of expansion of regimes and schemes, including the Marketing Authorisation Holder and Centralised Drug Procurement Scheme. We also welcomed the new Vaccine Administration Law and administrative regulations on Human Genetic Resources. For 2020, we expect new drug price management, adoption of the Unique Device Identification (UDI) System and amendments to drug registration regulation. In addition, there are likely to be developments to remote diagnosis and online hospitals, electronic medical insurance system and the amended Drug Administration Law.

We will be closely monitoring these ongoing developments and predictions during the course of the year, providing you with regular updates and analysis as they happen through our various free know-how platforms: our eAlert service, Law-Now, LinkedIn at ‘CMS Asia Pacific and CMS Life Sciences & Healthcare Sector’ and WeChat at ‘CMSAsia’.

For now, we hope you find our reflections and predictions of interest and help to your business as you plan for the year ahead.